• Advantages of personalized therapies in the treatment of bacterial vaginosis in women reproductive age 
To content

Advantages of personalized therapies in the treatment of bacterial vaginosis in women reproductive age 

HEALTH OF WOMAN. 2016.2(108):131–136; doi 10.15574/HW.2016.108.131 
 

Advantages of personalized therapies in the treatment of bacterial vaginosis in women reproductive age 
 

Tovstanovskyy V. O., Alatorskih A. E., Parsal Faranak

A.A. Bogomolets National Medical University, Kiev 
 

Objective: To determine the clinical effectiveness of personalized therapy compared to the standard regimen.


Materials and methods. Clinical, bacterioscopic, qualitative and quantitative PCR methods for the determination of conditionally pathogenic and pathogenic flora of the urogenital tract.


Results. Carrying personalized causal treatment, taking into account the sensitivity of detection of microorganisms associated with BV and their quantitative ratio, provides a lasting effect of treatment in 97.5% of cases.


Conclusion. Thus, a statistically significant normalization of, the group of patients whose treatment was carried out taking into account the vaginal flora associated with BV, testifies to the effectiveness of personalized therapy.


Key words: bacterial vaginosis, personalized therapy, the effectiveness.


REFERENCES

1. Kulakov VN. 2001. Practical Gynecology:186-200.

2. Ancyra AS. 2005. Bacterial vaginosis. Obstetrics and gynecology 6:13-16.

3. Mingalyov NV. 2008. Gynecological morbidity in modern conditions. Journal of Volgograd State Medical universiteta 3:72-74.

4. Andru B, Onderdone I, Kimberly U. 2008. Visseman Normal vaginal microflora. Harvard

5. Prilepskaya VN, Yaglov VV. 2007. Inflammatory diseases of the pelvic organs in the practice

6. Rosenstein IS, Kelin H, Avand N. 2007. Vaginal microbiological flora of pregnant women with bacterial vaginosis and its relationship to H202-producing strains of Lactobacillus spp. Int. J. AIDS. Number 8:8-9. http://dx.doi.org/10.1258/0956462971919499

7. Muslimov SZ. 2008. Modern notions of bacterial vaginosis: a review. Russian Gazette obstetrician-gynecologist. 8;1:13-17.

8. Paige DM, Augustyn M, Adih WK. 2008. Bacterial vaginosis and preterm birth: a comprehensive review of the literature. Nurse Midwifery 43(2):83-89. http://dx.doi.org/10.1016/S0091-2182(97)00161-4

9. Hashemi FB, Ghassemi M, Roebuck KA, Spear GT. 2009. Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis. J. Infect. Dis. 179(4):924-930. http://dx.doi.org/10.1086/314674; PMid:10068588

10. Joesoef MR, Schmid GP, Hillier SL. 2009. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin. Infect. Dis. 1:57-65.

11. Sidorova IS, Makarov IO, Matvienko NA. 2008. Intrauterine infection: prenatal care, delivery and postpartum period MEDpress-Inform:156.

12. Antroshkina ME, Ilina EN, Plakhova KI. 2009. Development of a DNA chip for the study of microbial communities. Molecular Medicine 3:23-31.

13. Fredricks D, Fiedler T, Thomas K. 2007. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. Journal Clinical Microbiology 45:32-70. http://dx.doi.org/10.1128/JCM.01272-07; PMid:17687006 PMCid:PMC2045326

14. Fredricks D. 2005. Molecular identification of bacteria associated with bacterial vaginosis. New England Journal of Medicine 353:1899 – 1911. http://dx.doi.org/10.1056/NEJMoa043802; PMid:16267321

15. Androsov LD, Kontorshchikova KN, Kudelkin SY. 2010. Characterization of biocenosis of the urogenital tract of women of reproductive age using test Femoflor. Medical almanac. 4:177-179.

16. Voroshilina EV, Tumbinskaya LV, Donnikov AE. 2010. Biocoenosis vagina in terms of quantitative PCR: changes and correction during pregnancy 3:108-111.

17. Martin D. 2013. Unique vaginal microbiota that includes an unknown Mycoplasma-like organism is associated with Trichomonas vaginalis infection. Journal Infection Deseases:1922-1931.

18. Wiesenfeld H, Hillier S, Krohn M. 2003. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis. Clinical Infections Desease 36:663-668. http://dx.doi.org/10.1086/367658; PMid:12594649

19. Verhelst R. 2004. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiology 4:16. http://dx.doi.org/10.1186/1471-2180-4-16; PMid:15102329 PMCid:PMC419343

20. Krausse R, Schubert S. 2010. In vitro activites of tetracycline, macrolides, ftouroquinolines and clindamycin against Mycoplasma hominis and Ureaplasma spp. Isolated in Germany over 20 years. Clinical Microbiology and Infectious Deseases 11:1649-1655. http://dx.doi.org/10.1111/j.1469-0691.2010.03155.x

21. Wilson J. 2004. Managing recurrent bacterial vaginosis. Sexual transmitted infections. 80:8-11. http://dx.doi.org/10.1136/sti.2002.002733; PMCid:PMC1758381

22. Balkhanov YS. 2009. Recovery options morphological and functional ability of the endometrium in women with recurrent miscarriages:24.

23. Gordeeva GD. 2005. Modern aspects of diagnosis and treatment of vaginal infections. Reproductive health 1:31-34.

24. Kocherovets VI, Bunyatyan VI. 2011. Normal microflora of the female urinary tract and the preparations for its correction. Tutorial:72.

25. Radzinsky VE. 2011. Two-stage vaginal therapy. Obstetrics and gynecology 5:90-93.

26. Mastromerino P, Vitali B, Mosca L. 2013. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiology:229-238.

27. Calleri LF. 2000. Vaginosi da Ureaplasma urealyticum e rottura premature delle membrane. Quale ruolo? Minerva Gynecology 52:49-58. PMid:10905076

28. Uvarova EV. 2003. Vagina – microecosystem both in normal and inflammatory processes of the genitals of different etiologies. Gynecology 4:189-195.

29. Danusevich IN, Popov S, Nadelyaeva EG. 2013. Kiev. Characterization of microbial factors genital tract in women with chronic endometritis and reproductive disorders. SWorld conference materials.

30. Drannik GN. 2006. Kiev. Clinical Immunology and Allergology:482.